An orally available small molecule inhibitor of Aurora kinases (AKs) A and B and other currently undisclosed kinases with potential antineoplastic and immunomodulatory activities. Upon oral administration, Aurora kinase inhibitor TT-00420 selectively binds to and inhibits AKs A and B, which may inhibit cell division in tumor cells that overexpress AKs. TT-00420 may also target other not yet disclosed kinases that play a role in tumor-associated inflammation and immune evasion. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types. [ ]